psilocybin
The U.S. Drug Enforcement Agency announced in late April 2024 that it plans to ease federal restrictions on cannabis, reclassifying it from a Schedule I drug to the less restricted Schedule III, which includes drugs such as Tylenol with codeine, testosterone and other anabolic steroids. This historic shift signals an acknowledgment of the promising medicinal value of cannabis. The move comes in tandem with growing interest in the use of psilocybin, the active component in magic mushrooms, for treatment of depression, chronic pain and other conditions. In 2018 and 2019, the U.S. Food and Drug A...
PsyPost (CA)
The U.S. Drug Enforcement Agency announced in late April 2024 that it plans to ease federal restrictions on cannabis, reclassifying it from a Schedule I drug to the less restricted Schedule III, which includes drugs such as Tylenol with codeine, testosterone and other anabolic steroids. This historic shift signals an acknowledgment of the promising medicinal value of cannabis. The move comes in tandem with growing interest in the use of psilocybin, the active component in magic mushrooms, for treatment of depression, chronic pain and other conditions. In 2018 and 2019, the U.S. Food and Drug A...
PsyPost
A recent case study published in Clinical Case Reports describes the journey of a 41-year-old woman who turned to psilocybin and MDMA to manage her debilitating post-COVID symptoms. The paper raises the intriguing possibility, which is far from certain, that psychedelic substances might help alleviate the psychological and cognitive symptoms associated with Long-COVID. Long-COVID, also known as post-acute sequelae of SARS-CoV-2 infection, encompasses a range of symptoms that persist well beyond the initial recovery from COVID-19. These symptoms can include fatigue, cognitive impairment, anxiet...
PsyPost
A recent case study published in Clinical Case Reports describes the journey of a 41-year-old woman who turned to psilocybin and MDMA to manage her debilitating post-COVID symptoms. The paper raises the intriguing possibility, which is far from certain, that psychedelic substances might help alleviate the psychological and cognitive symptoms associated with Long-COVID. Long-COVID, also known as post-acute sequelae of SARS-CoV-2 infection, encompasses a range of symptoms that persist well beyond the initial recovery from COVID-19. These symptoms can include fatigue, cognitive impairment, anxiet...
PsyPost (UK)
A recent case study published in Clinical Case Reports describes the journey of a 41-year-old woman who turned to psilocybin and MDMA to manage her debilitating post-COVID symptoms. The paper raises the intriguing possibility, which is far from certain, that psychedelic substances might help alleviate the psychological and cognitive symptoms associated with Long-COVID. Long-COVID, also known as post-acute sequelae of SARS-CoV-2 infection, encompasses a range of symptoms that persist well beyond the initial recovery from COVID-19. These symptoms can include fatigue, cognitive impairment, anxiet...
PsyPost (CA)
Recent research published in the journal Molecular Psychiatry has provided new insights into the potential therapeutic effects of psilocybin, a psychedelic compound, on cognitive flexibility and weight maintenance in a rat model of anorexia. The study found that psilocybin not only helps maintain body weight in female rats subjected to conditions mimicking anorexia nervosa but also enhances cognitive flexibility, particularly in adapting to changes in reward contingencies. Psilocybin is a naturally occurring psychedelic compound found in certain species of mushrooms, commonly known as “magic m...
PsyPost (CA)
Recent research published in the journal Molecular Psychiatry has provided new insights into the potential therapeutic effects of psilocybin, a psychedelic compound, on cognitive flexibility and weight maintenance in a rat model of anorexia. The study found that psilocybin not only helps maintain body weight in female rats subjected to conditions mimicking anorexia nervosa but also enhances cognitive flexibility, particularly in adapting to changes in reward contingencies. Psilocybin is a naturally occurring psychedelic compound found in certain species of mushrooms, commonly known as “magic m...
PsyPost (UK)
A recent pilot study published in the Journal of Psychedelic Studies has found preliminary evidence that psilocybin, when administered in a group retreat setting, can enhance psychological flexibility. The findings suggest that changes in psychological flexibility may play a crucial role in the therapeutic benefits of psilocybin experiences. Psilocybin is a naturally occurring psychedelic compound found in over 200 species of mushrooms, known colloquially as “magic mushrooms.” When ingested, psilocybin is converted into psilocin in the body, which then influences serotonin receptors in the bra...
PsyPost
A recent pilot study published in the Journal of Psychedelic Studies has found preliminary evidence that psilocybin, when administered in a group retreat setting, can enhance psychological flexibility. The findings suggest that changes in psychological flexibility may play a crucial role in the therapeutic benefits of psilocybin experiences. Psilocybin is a naturally occurring psychedelic compound found in over 200 species of mushrooms, known colloquially as “magic mushrooms.” When ingested, psilocybin is converted into psilocin in the body, which then influences serotonin receptors in the bra...
PsyPost (CA)
A recent pilot study published in the Journal of Psychedelic Studies has found preliminary evidence that psilocybin, when administered in a group retreat setting, can enhance psychological flexibility. The findings suggest that changes in psychological flexibility may play a crucial role in the therapeutic benefits of psilocybin experiences. Psilocybin is a naturally occurring psychedelic compound found in over 200 species of mushrooms, known colloquially as “magic mushrooms.” When ingested, psilocybin is converted into psilocin in the body, which then influences serotonin receptors in the bra...
PsyPost (UK)
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら